Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Eton, O.
Right arrow Articles by Benjamin, R. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eton, O.
Right arrow Articles by Benjamin, R. S.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Journal of Clinical Oncology, Vol 20, Issue 8 (April), 2002: 2045-2052
© 2002 American Society for Clinical Oncology

Sequential Biochemotherapy Versus Chemotherapy for Metastatic Melanoma: Results From a Phase III Randomized Trial

By Omar Eton, Sewa S. Legha, Agop Y. Bedikian, J. Jack Lee, Antonio C. Buzaid, Cynthia Hodges, Sigrid E. Ring, Nicholas E. Papadopoulos, Carl Plager, Mary Jo East, Feng Zhan, Robert S. Benjamin

From the Departments Melanoma/Sarcoma and Biostatistics, The University of Texas M.D. Anderson Cancer Center, and St Luke’s Episcopal Hospital, Houston, TX, and Oncology Center of the Hospital Sirio-Libanes, São Paulo, Brazil.

Address reprint requests to Omar Eton, MD, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 430, Houston, TX 77030; email: oeton{at}mdanderson.org

PURPOSE: The addition of cytokines to chemotherapy has produced encouraging results in advanced melanoma. In this phase III trial, we compared the effects of chemotherapy (cisplatin, vinblastine, and dacarbazine [CVD]) with those of sequential biochemotherapy consisting of CVD plus interleukin-2 and interferon alfa-2b.

PATIENTS AND METHODS: Metastatic melanoma patients who had not previously received chemotherapy were stratified by prognostic factors and given chemotherapy or biochemotherapy. CVD consisted of dacarbazine (days 1 and 22) and cisplatin and vinblastine (days 1 to 4 and 22 to 25). Biochemotherapy involved CVD with vinblastine reduced 25% plus interleukin-2 by 24-hour continuous infusion (on days 5 to 8, 17 to 20, and 26 to 29) and interferon alfa-2b by subcutaneous injection (on days 5 to 9, 17 to 21, and 26 to 30). Response was assessed every 6 weeks.

RESULTS: Among 190 patients enrolled, 91 were assessable for biochemotherapy and 92 for chemotherapy. Ten percent of the patients were alive a median of 52 months from start of therapy. Response rates were 48% for biochemotherapy and 25% for chemotherapy (P = .001); six patients given biochemotherapy and two given chemotherapy had complete responses. Median time to progression (TTP) was 4.9 months for biochemotherapy and 2.4 months for chemotherapy (P = .008); median survival was 11.9 and 9.2 months, respectively (P = .06). The influence of treatment on TTP and survival was confirmed in multivariate analyses with other prognostic factors not included in the original stratification. Biochemotherapy produced substantially more constitutional, hemodynamic, and myelosuppressive toxic effects.

CONCLUSION: Cytokines substantially augment the antitumor activity of chemotherapy at the expense of considerable toxicity in patients with metastatic melanoma.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
I. D. Davis, B. Brady, R. F. Kefford, M. Millward, J. Cebon, B. K. Skrumsager, U. Mouritzen, L. T. Hansen, K. Skak, D. Lundsgaard, et al.
Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial
Clin. Cancer Res., March 15, 2009; 15(6): 2123 - 2129.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. B. Atkins, J. Hsu, S. Lee, G. I. Cohen, L. E. Flaherty, J. A. Sosman, V. K. Sondak, and J. M. Kirkwood
Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group
J. Clin. Oncol., December 10, 2008; 26(35): 5748 - 5754.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. F. McDermott, J. A. Sosman, R. Gonzalez, F. S. Hodi, G. P. Linette, J. Richards, J. W. Jakub, M. Beeram, S. Tarantolo, S. Agarwala, et al.
Double-Blind Randomized Phase II Study of the Combination of Sorafenib and Dacarbazine in Patients With Advanced Melanoma: A Report From the 11715 Study Group
J. Clin. Oncol., May 1, 2008; 26(13): 2178 - 2185.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. J. Nemunaitis
Are Vaccines Making a Comeback in Non-Small-Cell Lung Cancer?
J. Clin. Oncol., March 20, 2008; 26(9): 1402 - 1403.
[Full Text] [PDF]

Home page
 JCOHome page
N. J. Ives, R. L. Stowe, P. Lorigan, and K. Wheatley
Chemotherapy Compared With Biochemotherapy for the Treatment of Metastatic Melanoma: A Meta-Analysis of 18 Trials Involving 2,621 Patients
J. Clin. Oncol., December 1, 2007; 25(34): 5426 - 5434.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. F. McDermott and M. B. Atkins
More Support for the Judicious Use of High-Dose Interleukin-2 in Patients With Advanced Melanoma
J. Clin. Oncol., September 1, 2007; 25(25): 3791 - 3793.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. D. Davis, B. K. Skrumsager, J. Cebon, T. Nicholaou, J. W. Barlow, N. P. H. Moller, K. Skak, D. Lundsgaard, K. S. Frederiksen, P. Thygesen, et al.
An Open-Label, Two-Arm, Phase I Trial of Recombinant Human Interleukin-21 in Patients with Metastatic Melanoma
Clin. Cancer Res., June 15, 2007; 13(12): 3630 - 3636.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
S. N. Markovic, L. A. Erickson, R. D. Rao, R. H. Weenig, B. A. Pockaj, A. Bardia, C. M. Vachon, S. E. Schild, R. R. McWilliams, J. L. Hand, et al.
Malignant Melanoma in the 21st Century, Part 2: Staging, Prognosis, and Treatment
Mayo Clin. Proc., April 1, 2007; 82(4): 490 - 513.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
M. A. Hofmann, W. Sterry, and U. Trefzer
Complex Combination Biochemotherapy Regimen in Advanced Metastatic Melanoma in a Non-intensive Care Unit: Toxicity or Benefit?
Jpn. J. Clin. Oncol., March 1, 2007; 37(3): 224 - 229.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Y. Bedikian, M. Millward, H. Pehamberger, R. Conry, M. Gore, U. Trefzer, A. C. Pavlick, R. DeConti, E. M. Hersh, P. Hersey, et al.
Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group
J. Clin. Oncol., October 10, 2006; 24(29): 4738 - 4745.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
L. Chin, L. A. Garraway, and D. E. Fisher
Malignant melanoma: genetics and therapeutics in the genomic era.
Genes & Dev., August 15, 2006; 20(16): 2149 - 2182.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Koyanagi, T. Mori, S. J. O'Day, S. R. Martinez, H.-J. Wang, and D. S.B. Hoon
Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients.
Cancer Res., June 15, 2006; 66(12): 6111 - 6117.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
M. B. Faries and D. L. Morton
The Promise of Metastasectomy in Melanoma
Ann. Surg. Oncol., May 1, 2006; 13(5): 607 - 609.
[Full Text] [PDF]

Home page
 Ann OncolHome page
E. Bajetta, M. Del Vecchio, P. Nova, A. Fusi, A. Daponte, M. R. Sertoli, P. Queirolo, P. Taveggia, M. G. Bernengo, S. S. Legha, et al.
Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-{alpha}2b in metastatic melanoma
Ann. Onc., April 1, 2006; 17(4): 571 - 577.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. B. Atkins
Cytokine-based therapy and biochemotherapy for advanced melanoma.
Clin. Cancer Res., April 1, 2006; 12(7): 2353s - 2358s.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. W. Weber, S. O'Day, M. Rose, R. Deck, P. Ames, J. Good, J. Meyer, R. Allen, S. Trautvetter, M. Timmerman, et al.
Low-Dose Outpatient Chemobiotherapy With Temozolomide, Granulocyte-Macrophage Colony Stimulating Factor, Interferon-{alpha}2b, and Recombinant Interleukin-2 for the Treatment of Metastatic Melanoma
J. Clin. Oncol., December 10, 2005; 23(35): 8992 - 9000.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. Koyanagi, S. J. O'Day, R. Gonzalez, K. Lewis, W. A. Robinson, T. T. Amatruda, H.-J. Wang, R. M. Elashoff, H. Takeuchi, N. Umetani, et al.
Serial Monitoring of Circulating Melanoma Cells During Neoadjuvant Biochemotherapy for Stage III Melanoma: Outcome Prediction in a Multicenter Trial
J. Clin. Oncol., November 1, 2005; 23(31): 8057 - 8064.
[Abstract] [Full Text] [PDF]

Home page
 Clin Med ResHome page
L. E. Raez, S. Fein, and E. R. Podack
Lung Cancer Immunotherapy
Clin. Med. Res., November 1, 2005; 3(4): 221 - 228.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
U. Keilholz, C. J.A. Punt, M. Gore, W. Kruit, P. Patel, D. Lienard, J. Thomas, T. M. Proebstle, A. Schmittel, D. Schadendorf, et al.
Dacarbazine, Cisplatin, and Interferon-Alfa-2b With or Without Interleukin-2 in Metastatic Melanoma: A Randomized Phase III Trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group
J. Clin. Oncol., September 20, 2005; 23(27): 6747 - 6755.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
K. Spanknebel, K. Y. Cheung, J. Stoutenburg, K. Hurst-Wicker, C. Hesdorffer, G. DeRaffele, and H. L. Kaufman
Initial Clinical Response Predicts Outcome and Is Associated With Dose Schedule in Metastatic Melanoma and Renal Cell Carcinoma Patients Treated With High-Dose Interleukin 2
Ann. Surg. Oncol., May 1, 2005; 12(5): 381 - 390.
[Abstract] [Full Text] [PDF]

Home page
 Arch SurgHome page
E. M. Noorda, B. C. Vrouenraets, O. E. Nieweg, B. N. van Geel, A. M. M. Eggermont, and B. B. R. Kroon
Isolated Limb Perfusion for Unresectable Melanoma of the Extremities
Arch Surg, November 1, 2004; 139(11): 1237 - 1242.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. J. Lewis
Therapeutic cancer vaccines: Using unique antigens
PNAS, October 5, 2004; 101(suppl_2): 14653 - 14656.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
H. Tsao, M. B. Atkins, and A. J. Sober
Management of Cutaneous Melanoma
N. Engl. J. Med., September 2, 2004; 351(10): 998 - 1012.
[Full Text] [PDF]

Home page
 JCOHome page
M. S. Mitchell
Chemotherapy for Melanoma: The Resultant of Conflicting Vectors
J. Clin. Oncol., June 1, 2004; 22(11): 2043 - 2045.
[Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
E. M. Noorda, B. Takkenberg, B. C. Vrouenraets, O. E. Nieweg, B. N. van Geel, A. M. M. Eggermont, G. A. M. Hart, and B. B. R. Kroon
Isolated Limb Perfusion Prolongs the Limb Recurrence-Free Interval After Several Episodes of Excisional Surgery for Locoregional Recurrent Melanoma
Ann. Surg. Oncol., May 1, 2004; 11(5): 491 - 499.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Yang and F. G. Haluska
Treatment of Melanoma with 5-Fluorouracil or Dacarbazine In Vitro Sensitizes Cells to Antigen-Specific CTL Lysis through Perforin/Granzyme- and Fas-Mediated Pathways
J. Immunol., April 1, 2004; 172(7): 4599 - 4608.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W.-J. Hwu, S. E. Krown, J. H. Menell, K. S. Panageas, J. Merrell, L. A. Lamb, L. J. Williams, C. J. Quinn, T. Foster, P. B. Chapman, et al.
Phase II Study of Temozolomide Plus Thalidomide for the Treatment of Metastatic Melanoma
J. Clin. Oncol., September 1, 2003; 21(17): 3351 - 3356.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Hauschild, M. Weichenthal, B.-R. Balda, J. C. Becker, H. H. Wolff, W. Tilgen, K.-W. Schulte, J. Ring, D. Schadendorf, S. Lischner, et al.
Prospective Randomized Trial of Interferon Alfa-2b and Interleukin-2 as Adjuvant Treatment for Resected Intermediate- and High-Risk Primary Melanoma Without Clinically Detectable Node Metastasis
J. Clin. Oncol., August 1, 2003; 21(15): 2883 - 2888.
[Abstract] [Full Text] [PDF]

Home page
 Arch Otolaryngol Head Neck SurgHome page
J. M. Owens, D. B. Roberts, and J. N. Myers
The Role of Postoperative Adjuvant Radiation Therapy in the Treatment of Mucosal Melanomas of the Head and Neck Region
Arch Otolaryngol Head Neck Surg, August 1, 2003; 129(8): 864 - 868.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
I. D. Davis, M. Jefford, P. Parente, and J. Cebon
Rational approaches to human cancer immunotherapy
J. Leukoc. Biol., January 1, 2003; 73(1): 3 - 29.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Biol. CellHome page
L. Staleva, P. Manga, and S. J. Orlow
Pink-eyed Dilution Protein Modulates Arsenic Sensitivity and Intracellular Glutathione Metabolism
Mol. Biol. Cell, December 1, 2002; 13(12): 4206 - 4220.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Belli, A. Testori, L. Rivoltini, M. Maio, G. Andreola, M. R. Sertoli, G. Gallino, A. Piris, A. Cattelan, I. Lazzari, et al.
Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings
J. Clin. Oncol., October 15, 2002; 20(20): 4169 - 4180.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. B. Atkins, J. A. Gollob, J. A. Sosman, D. F. McDermott, L. Tutin, P. Sorokin, R. A. Parker, and J. W. Mier
A Phase II Pilot Trial of Concurrent Biochemotherapy with Cisplatin, Vinblastine, Temozolomide, Interleukin 2, and IFN-{alpha}2B in Patients with Metastatic Melanoma
Clin. Cancer Res., October 1, 2002; 8(10): 3075 - 3081.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Koduri, M. A. Baumann, R. Ridolfi, and O. Nanni
Cisplatin and Dacarbazine With or Without Subcutaneous Interleukin-2 and Interferon Alfa-2b in Advanced Melanoma Outpatients
J. Clin. Oncol., August 15, 2002; 20(16): 3560 - 3561.
[Full Text] [PDF]

Home page
 JCOHome page
D. Khayat, C. Bernard-Marty, J.-B. Meric, and O. Rixe
Biochemotherapy for Advanced Melanoma: Maybe It Is Real
J. Clin. Oncol., May 15, 2002; 20(10): 2411 - 2414.
[Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2002 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online